You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
Copyright policy )Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
Background It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in SOT recipients. Results A total of 80 solid organ transplant (SOT) recipients completed a two-dose regimen with SARS-CoV-2 messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response six weeks after the second dose of vaccine. Conclusion This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination. This article is protected by copyright. All rights reserved.
- University of Southern Denmark Denmark
- Odense University Hospital Denmark
Microsoft Academic Graph classification: Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immune system Medicine Messenger RNA business.industry Immunogenicity Vaccination Regimen Immunology Solid organ transplantation business
COVID-19 Vaccines, immune response, Immunogenicity, Vaccine, vaccine, Research Letter, Internal Medicine, Humans, RNA, Messenger, Covid‐19, SARS-CoV-2, COVID-19, Organ Transplantation, Transplant Recipients, Covid-19, solid organ transplant recipient
COVID-19 Vaccines, immune response, Immunogenicity, Vaccine, vaccine, Research Letter, Internal Medicine, Humans, RNA, Messenger, Covid‐19, SARS-CoV-2, COVID-19, Organ Transplantation, Transplant Recipients, Covid-19, solid organ transplant recipient
Microsoft Academic Graph classification: Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immune system Medicine Messenger RNA business.industry Immunogenicity Vaccination Regimen Immunology Solid organ transplantation business
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).23 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10% citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).23 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!- University of Southern Denmark Denmark
- Odense University Hospital Denmark
Background It is currently not well described if a two-dose regimen of a Covid-19 vaccine is sufficient to elicit an immune response in SOT recipients. Results A total of 80 solid organ transplant (SOT) recipients completed a two-dose regimen with SARS-CoV-2 messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response six weeks after the second dose of vaccine. Conclusion This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid-19 vaccination. This article is protected by copyright. All rights reserved.